Cidara Interest Coverage vs Capex To Operating Cash Flow Analysis
CDTX Stock | USD 19.59 0.90 4.82% |
Cidara Therapeutics financial indicator trend analysis is way more than just evaluating Cidara Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cidara Therapeutics is a good investment. Please check the relationship between Cidara Therapeutics Interest Coverage and its Capex To Operating Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.
Interest Coverage vs Capex To Operating Cash Flow
Interest Coverage vs Capex To Operating Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cidara Therapeutics Interest Coverage account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Cidara Therapeutics' Interest Coverage and Capex To Operating Cash Flow is -0.19. Overlapping area represents the amount of variation of Interest Coverage that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of Cidara Therapeutics, assuming nothing else is changed. The correlation between historical values of Cidara Therapeutics' Interest Coverage and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Coverage of Cidara Therapeutics are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Interest Coverage i.e., Cidara Therapeutics' Interest Coverage and Capex To Operating Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.19 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Interest Coverage
Capex To Operating Cash Flow
Most indicators from Cidara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 54.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 14 M in 2024.
Cidara Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cidara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cidara Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 69.0M | 60.4M | 75.3M | 47.6M | 67.0M | 71.9M | |
Short Long Term Debt Total | 11.7M | 8.0M | 5.1M | 1.3M | 4.9M | 5.5M | |
Other Current Liab | 7.7M | 11.2M | 13.9M | 12.6M | 17.9M | 18.8M | |
Total Current Liabilities | 30.2M | 38.6M | 34.0M | 30.0M | 67.4M | 70.8M | |
Total Stockholder Equity | 37.8M | 10.7M | 21.6M | (2.9M) | (8.2M) | (7.8M) | |
Net Debt | (48.5M) | (28.0M) | (57.2M) | (31.4M) | (30.9M) | (32.4M) | |
Retained Earnings | (259.8M) | (334.7M) | (377.2M) | (407.0M) | (441.4M) | (419.4M) | |
Accounts Payable | 1.9M | 4.6M | 1.3M | 1.4M | 3.8M | 2.6M | |
Cash | 60.3M | 35.9M | 62.3M | 32.7M | 35.8M | 44.5M | |
Non Current Assets Total | 3.2M | 3.2M | 3.6M | 2.5M | 6.2M | 6.5M | |
Non Currrent Assets Other | 1.1M | 2.0M | 533K | 634K | 1.0M | 767K | |
Other Assets | 1.3M | 1.1M | 2.9M | 1.1M | 1.2M | 905.3K | |
Cash And Short Term Investments | 60.3M | 35.9M | 62.3M | 32.7M | 35.8M | 44.5M | |
Common Stock Shares Outstanding | 1.5M | 2.1M | 2.6M | 3.5M | 4.4M | 4.6M | |
Liabilities And Stockholders Equity | 69.0M | 60.4M | 75.3M | 47.6M | 67.0M | 71.9M | |
Non Current Liabilities Total | 942K | 11.1M | 19.7M | 20.5M | 7.8M | 8.5M | |
Other Current Assets | 5.5M | 10.1M | 6.7M | 13.1M | 2.7M | 4.5M | |
Other Stockholder Equity | 297.7M | 345.4M | 398.7M | 404.1M | 433.2M | 262.2M | |
Total Liab | 31.1M | 49.7M | 53.8M | 50.5M | 75.2M | 79.0M | |
Total Current Assets | 65.8M | 57.2M | 71.7M | 45.1M | 60.9M | 69.2M | |
Net Tangible Assets | 37.8M | 10.7M | 21.6M | (2.9M) | (2.6M) | (2.5M) | |
Property Plant And Equipment Net | 2.1M | 1.2M | 2.5M | 1.4M | 5.1M | 5.4M | |
Property Plant And Equipment Gross | 2.1M | 1.2M | 5.8M | 222K | 8.3M | 8.7M | |
Property Plant Equipment | 429K | 342K | 2.5M | 222K | 199.8K | 189.8K | |
Retained Earnings Total Equity | (218.7M) | (259.8M) | (334.7M) | (407.0M) | (366.3M) | (348.0M) | |
Capital Surpluse | 277.9M | 297.7M | 345.4M | 404.1M | 464.7M | 293.1M | |
Net Receivables | 5.5M | 11.2M | 5.4M | 5.8M | 16.2M | 17.1M | |
Short Long Term Debt | 9.9M | 10.0M | 7.0M | 2.6M | 2.3M | 2.2M | |
Short Term Debt | 10.8M | 8.9M | 4.9M | 1.2M | 2.6M | 5.1M | |
Net Invested Capital | 47.8M | 17.7M | 24.2M | (2.9M) | (8.2M) | (7.8M) | |
Net Working Capital | 35.6M | 18.6M | 37.7M | 15.1M | (6.6M) | (6.2M) | |
Current Deferred Revenue | 9.8M | 13.9M | 13.9M | 14.6M | 25.1M | 15.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.